<DOC>
	<DOCNO>NCT00005616</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient colorectal cancer .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity associate increase single dos monoclonal antibody F19 ( BIBH-1 ) administer intravenous infusion patient colorectal cancer schedule surgical resection . II . Compare pharmacokinetics , biodistribution , image characteristic increase intravenous dos iodine I 131 BIBH-1 patient population . III . Compare BIBH-1 related human antihuman antibody ( HAHA ) serum concentration immunologic related clinical effect patient . IV . Compare uptake iodine I 131 BIBH-1 tumor uptake normal tissue administer patient . OUTLINE : This dose escalation study . Patients receive monoclonal antibody F19 ( BIBH-1 ) combine iodine I 131 IV 60 minute . Patients undergo surgical resection approximately 7 day BIBH-1 infusion . Cohorts 3-6 patient receive escalate dos BIBH-1 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow day 5-14 day 30 surgery . PROJECTED ACCRUAL : A total 12 patient accrue study within 4 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary colorectal cancer Candidate clinically indicate laparotomy primary tumor resection , resection hepatic metastasis , placement intrahepatic arterial catheter No active CNS metastasis define new enlarge lesion CT scan within 3 month treatment ( i.e. , surgery radiotherapy ) brain metastases No prior participation study PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 3 month Hematopoietic : Granulocyte count least 2,500/mm3 Lymphocyte count great 700/mm3 Platelet count least 100,000/mm3 Hepatic : ALT/AST great 3 time upper limit normal Bilirubin le 2 mg/dL Renal : Creatinine great 2.0 mg/dL Other : No pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No incomplete heal incision site evidence incomplete granulation , infection , localize edema No active infection require antibiotic No bleed disorder No serious illness may potentially interfere obtain accurate study result No autoimmune disease No hypertrophic skin condition PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy No prior murine , chimeric , humanize antibody and/or antibody fragment Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : No concurrent systemic corticosteroid except acute management allergic type event Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Recovered prior surgery Other : At least 4 week since prior investigational agent No concurrent immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>